Minakem Header W48

Minakem Header W48

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Innovent Biologics

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Innovent Announces First Patient Dosed in A Phase 1b/2 Clinical Trial of IBI362, a Dual GLP-1 and Glucagon Receptor Agonist, in China

Details:

CIBI362B101 is a multiple-dose, safety and tolerability, pharmacokinetics and pharmacodynamics clinical study of IBI362 conducted in overweight or obese subjects in China.

Lead Product(s): IBI362

Therapeutic Area: Nutrition and Weight Loss Product Name: IBI362

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 18, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY